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Abstract
Background: Soy isoflavones show structural and functional similarities to estradiol. Available data indicate that estradiol and
estradiol-like components may interact with gut "satiety hormones" such as peptide YY (PYY) and ghrelin, and thus influence
body weight. In a randomized, double-blind, placebo-controlled, cross-over trial with 34 healthy postmenopausal women (59 ±
6 years, BMI: 24.7 ± 2.8 kg/m2), isoflavone-enriched cereal bars (50 mg isoflavones/day; genistein to daidzein ratio 2:1) or non-
isoflavone-enriched control bars were consumed for 8 weeks (wash-out period: 8-weeks). Seventeen of the subjects were
classified as equol producers. Plasma concentrations of ghrelin and PYY, as well as energy intake and body weight were measured
at baseline and after four and eight weeks of each intervention arm.
Results: Body weight increased in both treatment periods (isoflavone: 0.40 ± 0.94 kg, P < 0.001; placebo: 0.66 ± 0.87 kg, P =
0.018), with no significant difference between treatments. No significant differences in energy intake were observed (P = 0.634).
PYY significantly increased during isoflavone treatment (51 ± 2 pmol/L vs. 55 ± 2 pmol/L), but not during placebo (52 ± 3 pmol/
L vs. 50 ± 2 pmol/L), (P = 0.010 for treatment differences, independent of equol production). Baseline plasma ghrelin was
significantly lower in equol producers (110 ± 16 pmol/L) than in equol non-producers (162 ± 17 pmol/L; P = 0.025).
Conclusion: Soy isoflavone supplementation for eight weeks did not significantly reduce energy intake or body weight, even
though plasma PYY increased during isoflavone treatment. Ghrelin remained unaffected by isoflavone treatment. A larger and
more rigorous appetite experiment might detect smaller differences in energy intake after isoflavone consumption. However,
the results of the present study do not indicate that increased PYY has a major role in the regulation of body weight, at least in
healthy postmenopausal women.
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Several intervention studies in humans and animals sug-
gest that consumption of soy and isoflavone-rich soy pro-
tein may decrease body weight [1,2]. Postmenopausal
women with relatively high isoflavone consumption in
their normal diet showed an inverse association with
obesity in a cross-sectional study [3]. However, the pro-
tein content of soy may be at least partly responsible for
the observed effects, and the contribution of soy isofla-
vones such as genistein and daidzein remains uncertain
[4,5]. There is some evidence that may link isolated isofla-
vone consumption per se to the regulation of body weight.
Soy isoflavones show functional and structural similari-
ties to estradiol [6], mainly by binding to the estrogen
receptor β [7]. In ovariectomized mice, loss of circulating
estrogen increases body weight and fat mass, and this is
reversed by estrogen replacement [8,9]. Similar effects
have been observed in ovariectomized mice treated with
oral genistein [10,11]. Even though the role of postmeno-
pausal hormone replacement in modulating body weight
is controversial [12,13], some studies indicate that the
activation of the estrogen receptor interferes with the reg-
ulation of gut hormones commonly thought to be
involved in the regulation of food intake. Food intake
decreases during the high estrogen period in the estrous
cycle in rats, and estradiol replacement in ovariectomized
rats increased the satiating effect of the gut hormone
cholecystokinin [14]. Estrogen replacement in hysterect-
omized postmenopausal women also increased periph-
eral concentrations of the orexigenic gut hormone ghrelin
[15]. Peptide YY (PYY), a member of the neuropeptide Y
(NPY) family and another gut derived "satiety hormone",
is assumed to have potent anorexigenic properties, with
potential therapeutic use in obese humans [16]. Human
PYY has been shown to be regulated in a gender specific
manner, with higher PYY secretion in females than in
males [17]. Treatment of ovariectomized rodents with
estradiol increases the number of receptors of several neu-
ropeptides, including NPY receptors in the brain [18]. To
date, potential effects of isolated isoflavones on PYY have
not been reported, and only one study investigated effects
of isolated isoflavones on total ghrelin concentrations
[19]. In addition, no long-term randomized controlled
studies have investigated whether changes in PYY concen-
trations influence food intake in free living humans. The
hypothesis of the present study was that estradiol-like
properties of isolated isoflavones may influence PYY and
ghrelin, and thus energy intake and body weight.
Results
Results of biomarkers are given as postabsorptive concen-
trations, measured after a standardized low-fat evening
meal and after 12 h overnight fasts. P values for PYY, glu-
cose, insulin and ghrelin are given for the treatment effect
within a linear mixed model. Differences from baseline
were used as response variable after adjustment for
changes in BMI.
Dietary intake and body weight
Dietary intake was assessed at baseline and after four
weeks of each intervention arm. Macronutrient intake at
baseline was 15% of energy as protein, 34% as fat, and
47% as carbohydrate. Even though participants were
instructed to replace snacks by the cereal bars, body
weight increased moderately, but significantly, during
both intervention periods (placebo + 0.66 ± 0.87 kg, (P =
0.018); isoflavones + 0.40 ± 0.94 kg, (P < 0.001)). There
was no significant difference in body weight and body
mass index (P > 0.331) between treatments (table 1).
There were no significant differences in energy intake or
macronutrient intake, both across the treatments and
compared to baseline (wk4 - wk0; interaction treatment
vs. time, P = 0.634).
Effect of isoflavone consumption on PYY
During isoflavone consumption, PYY concentrations
increased by eight percent, and during placebo consump-
tion, PYY concentrations decreased by four percent (P =
0.010 for treatment differences) (table 1).
Changes in PYY levels were independent of changes in
BMI, and were negatively correlated with baseline PYY (r
Table 1: Plasma PYY, body weight, and urinary isoflavone concentrations in postmenopausal women, at baseline (t0) and after 8 weeks 
(t8) of isoflavone or placebo consumption (n = 34)
Isoflavones Placebo P value1
t0 t8 t0 t8
Total PYY (pmol/L) 51 ± 2 55 ± 2 52 ± 3 50 ± 2 0.010
BMI (kg/m2) 24.5 ± 2.7 24.6 ± 2.7 24.5 ± 2.8 24.7 ± 2.8 0.331
Glucose (mmol/L) 5.7 ± 0.1 5.6 ± 0.1 5.7 ± 0.1 5.6 ± 0.1 0.641
Insulin (pmol/L) 37 ± 3 39 ± 3 38 ± 3 34 ± 3 0.231
Total ghrelin (pmol/L) 129 ± 12 131 ± 12 133 ± 13 123 ± 11 0.297
Data are given as mean ± SEM except for BMI which is presented as mean ± SD. BMI = body mass index.
1 P values are shown for the treatment effect within a linear mixed model. Differences from baseline were used as response variable after 
adjustment for changes in BMI.Page 2 of 6
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cantly different between equol producers and equol non-
producers.
Effect of isoflavone consumption on ghrelin
At baseline, ghrelin was significantly lower in equol pro-
ducers (110 ± 16 pmol/L) than in equol non-producers
(162 ± 17 pmol/L); (P = 0.025), independent of BMI.
However, isoflavone treatment did not affect ghrelin con-
centrations (table 1).
Other parameters
During isoflavone treatment, urinary genistein and daid-
zein excretion increased 15 fold and 24 fold, respectively.
There was no significant increase in urinary genistein and
daidzein concentrations following placebo treatment.
According to the cut-offs used in the present study [20], 50
percent of the participants (n = 17) were classified as
equol producers. Equol production increased 35 fold in
equol producers during the active treatment, compared to
an 1.7 fold increase in equol non-producers (table 2).
Plasma glucose and insulin were unaffected by isoflavone
treatment (table 1).
Power analysis
A between-treatment difference in body weight > 500 g
after 8 weeks intervention was assumed to be relevant. The
estimated power of this study was 94 percent to detect a
difference of 500 ± 900 g in body weight between treat-
ments with a sample size of 34 subjects and a significance
level of 0.05.
Discussion
Consumption of soy derived food rich in isoflavones has
been suggested to have favorable effects on energy intake
and body weight [5]. However, soy derived food is also
rich in protein, and an increased protein intake might be
responsible for the observed effects. The potential contri-
bution of isolated isoflavones to the regulation of energy
and body weight remains uncertain. In the present study,
isoflavone treatment for eight weeks did not significantly
influence energy intake, macronutrient intake, or body
weight, both across the treatments or compared to base-
line. Isoflavone treatment did not affect preprandial ghre-
lin, which seems to be in contrast to results of a previous
study that investigated effects of isoflavone treatment on
ghrelin concentrations [19]. However, the observed differ-
ences in the mentioned study are mainly due to increased
ghrelin concentrations in the placebo group rather than
altered ghrelin concentrations after isoflavone intake. In
addition, high within and between subject variations in
preprandial ghrelin concentrations have been reported,
which may lead to the detection of random effects rather
than of true treatment effects [21]. Despite unchanged
ghrelin concentrations during isoflavone treatment in the
present study, the ability of producing equol, a gut bacte-
rial metabolite of daidzein with higher binding affinity to
estrogen receptors compared with its precursor [22], was
associated with lower ghrelin concentrations at baseline.
The capability to produce equol is greatly varying between
individuals, with about 30–40% equol producers in the
Western population [22]. It is speculated that equol pro-
ducers may have an increased benefit from soy consump-
tion [20,23]. However, even though the ability of
producing equol was associated with lower ghrelin con-
centrations at baseline, ghrelin responses remained unaf-
fected during isoflavone treatment in the present study.
This indicates that equol may have a long-term suppres-
sive effect on ghrelin concentrations, which probably will
not respond to further and relatively short-term increases
of equol concentrations. In contrast to unchanged ghrelin
in the present study, isolated soy isoflavones significantly
increased plasma PYY concentrations. Given the assumed
potent anorexigenic properties of PYY [16], our data do
not suggest a major role of PYY on the regulation of body
weight. Notably, power analysis indicated that even a
moderate difference in body weight between treatments
was highly likely to be detected. Only moderate effects of
PYY on the regulation of body weight may contribute to
the explanation of controversial findings in the literature.
In humans, short-term intravenous administration of PYY
Table 2: Urinary isoflavone concentrations in postmenopausal women at baseline (t0) and week 8 (t8) of isoflavone and placebo arms 
(n = 34)
Isoflavones Placebo P value1
t0 t8 t0 t8
Genistein (nmol/L) 808 ± 134 12266 ± 852 655 ± 68 647 ± 73 <0.001
Daidzein (nmol/L) 334 ± 88 8146 ± 651 315 ± 82 223 ± 40 <0.001
Equol, (nmol/L) 154 ± 12 3040 ± 713 162 ± 15 198 ± 23 <0.001
Equol producers (n 
= 17)
164 ± 11 5834 ± 749 179 ± 16 237 ± 29 <0.001
Equol non-
producers (n = 17)
143 ± 14 245 ± 16 145 ± 13 160 ± 12 <0.001
Data are given as mean ± SEM.
1 P values are shown for the treatment effect within a linear mixed model. Differences from baseline were used as response variable.Page 3 of 6
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logical doses [25] reduces appetite and food intake. Long-
term studies in humans are not available to date. A two
weeks continous PYY infusion in colectomized rats did
not affect food intake and body weight [26], and data
obtained from other animal studies are controversially
discussed [27]. The duration of the present study may
have been too short to detect relevant differences in body
weight. However, most studies linking physiological ghre-
lin and PYY responses to food intake investigated the
effects of only one meal. A relatively small but well per-
formed study over 16 weeks did not show an effect of
macronutrient intake and energy intake on preprandial
ghrelin [21]. It needs, however, to be emphasized that
food diaries, and not weighed food intake were used to
assess energy intake in the present study, and a more rig-
orous appetite experiment might detect smaller effects. In
addition, adaptation processes and counter regulatory
responses in other satiety hormones than total ghrelin,
such as acylated ghrelin, glucagon-like peptide (GLP-1),
or cholecystokinin may have masked detectable differ-
ences in energy intake or body weight.
Conclusion
Isoflavone treatment had no effect on energy intake and
body weight, despite significantly increased preprandial
PYY concentrations. The findings indicate that PYY is not
a major factor in the regulation of body weight. Prepran-
dial ghrelin was not affected by isoflavone consumption.
The isoflavone contents are not likely to explain the
observed beneficial effects of soy consumption on energy
intake and body weight.
Methods
Subjects
This study was part of a multi-center intervention located
in Frederiksberg (Denmark), Reading (UK), Rome (Italy),
and Potsdam (Germany). Potential effects of isoflavones
on gut satiety hormones and body weight were investi-
gated in the German population. Thirty-six healthy post-
menopausal women (age 59 ± 6 y, BMI 24.7 ± 2.8 kg/m2),
defined as at least 12 months since the last menstrual
cycle, were recruited by advertisement in the local media.
Thirty-four of the subjects completed the intervention.
One of the subjects was excluded because of a prolonged
respiratory infection, the other one because of start of a
treatment with an angiotensin-converting-enzyme inhibi-
tor. None of the volunteers had used hormone replace-
ment therapy for six months, antibiotics for three months,
or isoflavone, vitamin, or mineral containing supple-
ments for two months. All volunteers were non-smokers.
Parameters of renal and liver function were within normal
range. Subjects were classified as equol producers, when
equol in a 24 h urine sample exceeded 936 nmol/liter dur-
ing isoflavone treatment, which corresponds to an urinary
equol excretion of > 0.45 mg/day [20]. The study protocol
was approved by the Ethics Committee of the University
of Potsdam, Germany. All volunteers gave written
informed consent prior to the study.
Study design
This was a randomized, double-blind, placebo-control-
led, 2 × 8-wk crossover study, separated by an 8-wk wash-
out period. Subjects were invited to the metabolic unit on
6 occasions (t0, t4, and t8 on each intervention arm), after
12-h overnight fasts. To exclude potential second-meal
effects, a set low-fat evening meal (< 10 g fat) was con-
sumed the evening before each of the study days. Recipes
for the preparation of the meals were provided to the par-
ticipants. Energy contents of the meals were comparable.
Subjects were asked to consume two fruit cereal bars/d
(Health & Diet Food, Manchester, UK), one in the morn-
ing and one in the afternoon, in addition to their normal
diet. During the treatment period, cereal bars were
enriched with 2 × 25 mg isoflavones/d, with a genistein to
daidzein ratio of 2:1 ("Solgen 40", Solbar Plant Extracts,
Ashdod, Israel). Thus, isoflavone intake in the treatment
group of the present study was in the upper range of the
daily isoflavone intake in traditional Asian diets (15 – 50
mg/d) [28]. The product was tested before packaging and
during the study by HPLC, to ensure stability of the isofla-
vones [29]. Placebo did not contain any isoflavones. Each
cereal bar (40 g) had an average nutrient content of energy
(652 kJ); protein 2.6 g; carbohydrate 17.3 g; fat 8.5 g; fiber
1.8 g; sodium 0.012 g. Subjects perceived the isoflavone-
enriched and placebo cereal bars as identical in taste and
visual appearance. Habitual diet was assessed by esti-
mated 3-d food records three times during the study. Diet
diaries were completed at baseline (t0) and after 4 weeks
(t4) of each intervention arm. All food records included
two week days and one weekend day. Nutrient intake was
calculated based on the German Food and Nutrient Data
Base Bundeslebensmittelschlüssel BLS II.3 [30]. To avoid
weight gain, subjects were advised to replace snacks with
the cereal bars. Subjects kept daily records of cereal bar
consumption and well-being in a study diary. Dietary
compliance was further assessed by measurement of phy-
toestrogen concentrations in 24-hour urine [31], which
was collected at start and end of each intervention period.
Body weight was measured at each visit.
Biochemical parameters
Blood was collected in ice-chilled EDTA tubes for the anal-
ysis of glucose, ghrelin, and PYY. Following centrifugation
at 1600 g for 10 minutes at 4°C, aliquots were immedi-
ately frozen at -20°C until assayed. All samples from indi-
vidual subjects were measured in the same assay.
Immunoreactive total ghrelin was measured by a com-
mercially available radioimmunoassay (Phoenix Pharma-
ceuticals, Mountain View, CA, USA), as previouslyPage 4 of 6
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measured by a commercially available radioimmunoassay
(LINCO Research, Missouri, USA), using125I-labeled bio-
active PYY as tracer and a PYY antiserum to determine the
level of active PYY by the double antibody/PEG tech-
nique. The PYY antibody is raised in guinea pigs and rec-
ognizes both the PYY 1–36 and PYY 3–36 forms of human
PYY. Intra- and inter-assay coefficient of variation was
5.3% and 7.0%, respectively. Insulin, and glucose, and
urinary phytoestrogens (genistein, daidzein, equol) were
analyzed as previously described [33].
Statistical analyses
Data are given as mean ± SEM, anthropometric data are
given as mean ± SD. Changes from baseline, e.g. week-8
compared to week-0 (t8-t0), were used as the dependent
variables. Data were calculated as changes from baseline
on the original scale, when normally distributed. Skewed
data where log transformed, and changes from baseline
on the log scale were calculated, and these changes now
correspond to a multiplicative change from baseline on
the original scale. Subjects were included as a random fac-
tor within a linear mixed model. Fixed effects included in
the final model were: baseline parameters, treatment,
treatment order, and changes in BMI. Further exploratory
investigation of equol group was included in the model.
Pearson's correlation coefficient was calculated between
baseline PYY and changes in PYY. Statistical analysis was
performed using SAS 8.4 (SAS Institute Inc., Cary, NC).
Abbreviations
BMI: body mass index; PYY: peptide YY.
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